Online inquiry

IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7133MR)

This product GTTS-WQ7133MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000233.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3973
UniProt ID P22888
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7133MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4943MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ13242MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ13636MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ12447MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ1195MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ8916MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ2988MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ10669MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW